Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Inc.

www.pfizer.com

Latest From Pfizer Inc.

Stockwatch: Coronavirus Takes A Bite Out Of AstraZeneca’s Guidance, GSK and AbbVie Get Spinning

The Coronavirus outbreak makes its first dent into pharma's 2020 prospects as AstraZeneca admits possible impact, while could AbbVie's aesthetic plans raise the prospect of another GSK-style spin off? 

Stockwatch Companies

US OTC Switch Drought Ends: FDA Approves GSK Arthritis Gel, Alcon Allergy Eye Drops

FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.

OTC Drugs Prescription To Otc Switch

Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics

Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…

Deals Business Strategies

AstraZeneca Returns To Growth, But Coronavirus Likely To Hit China Revenues

With a long turnaround process now complete, AstraZeneca could hit double digit growth in 2020, thanks to existing products and new approvals such as roxadustat. 

Sales & Earnings Strategy
See All

Company Information

UsernamePublicRestriction

Register